MED
MEDIFAST INC
NYSE: MED · CONSUMER CYCLICAL · PERSONAL SERVICES
$12.48
-1.05% today
Updated 2026-06-03
Market cap
$134.54M
P/E ratio
—
P/S ratio
0.39x
EPS (TTM)
$-1.82
Dividend yield
—
52W range
$9 – $15
Volume
0.2M
WallStSmart proprietary scores
45
out of 100
Grade: C
Sell
Investment rating
2.0
Growth
F8.5
Quality
A2.0
Profitability
F6.0
Valuation
B2/9
Piotroski F-Score
Weak
5.0
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$12.00
-3.85%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Altman Z 4.98 — safe zone
+ Debt/equity 0.08x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at -5.79%
- Negative free cash flow $-836000.00
- Revenue declining -34.30% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.60B | $1.07B | $602.46M | $385.79M | $346.10M |
| Net income | $143.57M | $99.42M | $2.09M | $-18.67M | $-2.12M |
| EPS | — | — | — | — | $-1.82 |
| Free cash flow | $177.89M | $141.17M | $17.02M | $1.25M | $-836000.00 |
| Profit margin | 8.98% | 9.27% | 0.35% | -4.84% | -5.79% |
Peer comparison
Smart narrative
MEDIFAST INC trades at $12.48. Our Smart Value Score of 45/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 4.98, it sits in the safe zone. TTM revenue stands at $346.10M. with profit margins at -5.79%.
Frequently asked questions
What is MEDIFAST INC's stock price?
MEDIFAST INC (MED) trades at $12.48, on a P/S of 0.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is MEDIFAST INC overvalued?
MEDIFAST INC carries a Smart Value Score of 45/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of MEDIFAST INC (MED)?
The 12-month analyst consensus target is $12.00, about 3.8% below the current $12.48. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is MEDIFAST INC's revenue?
MEDIFAST INC's trailing twelve-month revenue is $346.10M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
MEDIFAST INC's Altman Z-Score is 4.98, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorCONSUMER CYCLICAL
IndustryPERSONAL SERVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio0.39x
ROE-10.13%
Beta0.66
50D MA$11.39
200D MA$11.84
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—